MAM
Medikabazaar announces R K Narayanan as VP-business partner
Mumbai: Medikabazaar, a B2B medical supplies platform, has announced the appointment of four senior executives to strengthen its leadership team across the country.
R K Narayanan has joined Medikabazaar as the vice president-business partner for its Value Purchase Organization (VPO) business. He will be responsible for supporting the creation of product segments in equipment and devices and expand customer offerings across the VPO business.
Narayanan comes with 30 years of rich experience in expanding the business and has previously worked with Boston Scientific handling upstream marketing & CTO programs. He has had stints with companies like Philips Healthcare, GE Healthcare, and Indchem Electronics.
In a bid to expand its presence, Medikabazaar plans to double its workforce by the end of this financial year in line with its aggressive growth plans, the platform said in a statement.
In another key appointment in the VPO business, Manu Dixit joins Medikabazaar as the business head for the South and West regions. Dixit will be responsible for OEM tie-ups and will address the procurement needs of all medium and small-size hospitals across the region. He has worked with brands such as Johnson & Johnson, GlaxoSmithKline, and Zydus.
The other two business heads who have joined Medikabazaar are Rakesh Gurkha and Chaitanya Sapkal. While Gurkha will be leading the business along with the current Dental Sales team across regions, Sapkal will look into spearheading and expanding the diagnostic business across India.
Gurkha comes with over 22 years of experience in sales and has been associated with companies like Cortex Dental Implant Industries, Acteon, Danaher & the Kavo Group. Sapkal commands over 20 years of experience in handling sales in the West and South regions and has worked with brands like Abbott Healthcare, Johnson & Johnson, Roche Diagnostics, and Trivitron Diagnostics.
“We are thrilled to have this dynamic team join us at such an important juncture in Medikabazaar’s growth journey,” said Medikabazaar CEO & founder Vivek Tiwari. “The new leadership team holds a strong professional track record and cultural connect with the local markets, which I am confident will further help us move strongly towards achieving our mission of ensuring that, people have access to innovative and quality health treatment.”
Risk and return maintain inverse proportionality within mutual funds – higher potential rewards accompany elevated volatility, while stability demands lower expectations. SEBI’s Riskometer (1-5 scale) standardizes visualization, but quantitative metrics reveal nuanced relationships across categories and market cycles.
Fundamental Risk-Return Relationship
Equity funds (Riskometer 4-5) deliver historical 12-16% CAGR alongside 18-25% standard deviation—large-cap 15% volatility, small-cap 30%+. Debt funds (1-2) yield 6-8% with 2-6% volatility. Hybrids (3) average 9-12% returns, 10-14% volatility.
Sharpe ratio measures return per risk unit – equity 0.7-0.9, debt 0.5-0.7 over complete cycles. Higher risk categories compensate through return premium capturing economic growth.
Volatility Metrics Explained
Standard Deviation: Annual NAV return dispersion—equity 18-22%, debt 4-6%.
Maximum Drawdown: Peak-to-trough losses – equity 50%+ (2008), debt 8-12%.
Beta: Market sensitivity – equity 0.9-1.1, debt 0.1-0.3.
Sortino Ratio focuses downside volatility—equity 1.0-1.3 favoring recoveries.
Value at Risk (VaR) estimates 95% confidence, worst 1-month loss: equity 10-15%, debt 1-2%.
Category Risk-Return Profiles
Large-cap equity: 12-14% CAGR, 15% volatility, Sharpe 0.8.
Mid/small-cap: 15-18%, 22-30% volatility, Sharpe 0.7.
Corporate bond debt: 7-8%, 4% volatility, Sharpe 0.6.
Liquid funds: 6.5%, <1% volatility—capital preservation.
Credit risk debt: 8.5%, 6% volatility—yield pickup.
Hybrids: 10-12%, 12% volatility—balanced exposure.
Review types of mutual funds specifications confirming mandated asset allocations driving profiles.
Historical Risk-Return Tradeoffs (2000-2025)
Complete cycles: Equity 14% CAGR/18% volatility; 60/40 equity/debt 11%/11% volatility; debt 7.5%/5% volatility. Bull phases (2013-2021): equity 18%, debt 8%. Bear markets (2008, 2020): equity -50%/+80% swings, debt -10%/+10%.
Inflation-adjusted: Equity 8% real CAGR; debt 1.5% real—growth funding requires equity allocation.
Risk Capacity Assessment Framework
Short-term goals (1-3 years): Riskometer 1-2 (liquid/debt), 2-4% real returns. Medium-term (5-7 years): Level 3 (hybrid), 4-6% real. Long-term (10+ years): Level 4-5 (equity), 6-9% real.
Personal factors: Age (younger = higher risk), income stability, emergency fund coverage, other assets. Drawdown tolerance—20% comfortable vs 40% discomfort signals capacity limits.
Portfolio Construction Principles
Diversification: 60/40 equity/debt reduces volatility 40% versus equity-only while capturing 80% returns.
Correlation: Equity/debt 0.3 average enables smoothing.
Rebalancing: Annual drift correction sells outperformers (equity +25%), buys underperformers (debt -5%).
Style balance: Large-cap stability offsets mid-cap growth volatility.
Quantitative Risk Management Tools
Sharpe Ratio: >1.0 indicates efficient risk-taking.
Information Ratio: Alpha per tracking error.
Downside Deviation: Focuses losses only.
Stress Testing: 2008 scenario simulations reveal portfolio behavior extremes.
Conclusion
Higher mutual fund risk levels correlate with elevated return potential – equity 12-16% amid 18-25% volatility versus debt 6-8%/4-6%. Risk capacity matching, category diversification, rebalancing discipline, and quantitative metric interpretation align portfolios with personal tolerance across economic cycles.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
